Waters Corporation enters June caught between two powerful and competing forces: a surging rally that has pushed the stock up 21% over the past month, and a sharp jump in short interest that suggests not everyone believes the move is justified.
The price chart is unambiguous. WAT closed Tuesday at $371.93, up nearly 10% on the week and more than 21% over the past month — a run powered by a blowout Q1 earnings print on May 5 that sent the stock up 15.8% in a single session. The five-day return after that print extended to 16.7%. That kind of magnitude is rare. The question the market is now asking is whether the underlying fundamentals support a stock that has re-rated this aggressively.
Short sellers are not yet convinced. Short interest climbed 24% in the past week to reach 6.9% of the free float — one of the most rapid weekly buildups in the recent history of this name. From mid-May levels near 3.3–3.4% of float, SI has effectively doubled in the space of six sessions, rising from roughly 3.33 million shares to 4.13 million. That is a meaningful repositioning, not a rounding error. The ORTEX short score has also drifted higher, moving from around 37 in mid-May to 41 this week. Borrow conditions, however, offer little friction for that fresh positioning — cost to borrow sits near 0.47%, low by any standard, and availability is extraordinarily loose at over 1,000%. Every new short can be established cheaply. There is no squeeze pressure of any kind in the lending market.
Options positioning has shifted meaningfully bullish, which cuts against the short thesis. The put/call ratio dropped to 0.58 — well below its 20-day average of 0.75, and more than 1.3 standard deviations below that mean. Six weeks ago, before the May earnings catalyst, PCR was running near 0.95. Calls now dominate flow by a wide margin, reflecting either hedged long positions rolling up strikes, or fresh directional buying into the rally. That divergence — shorts building aggressively while options traders lean bullish — is the central tension in WAT's positioning this week.
The Street is broadly upgrading its view but stopping short of wholesale conviction. HSBC raised its price target to $435 and kept a Buy rating today, while Wolfe Research initiated coverage with an Outperform and a $425 target. B of A Securities lifted its target to $400 but held at Neutral — a cautious acknowledgement that the rally has run faster than the fundamentals warrant at current multiples. The consensus mean target is $399, implying roughly 7% upside from Tuesday's close. The P/E multiple has expanded to 24.3x, up more than four points over the past 30 days, and the EV/EBITDA ratio, now near 16.9x, is elevated relative to the sector. EPS momentum scores rank in the 62nd percentile, and the 12-month forward EPS growth trajectory ranks at the 85th percentile — supportive numbers, but not the kind that ordinarily justify a 21% monthly move without some multiple risk. That valuation tension is precisely where the building short interest seems to be anchored.
The FDA clearance of the BD BACTEC FXI Culture System, announced today, adds a fresh product catalyst to the bull narrative — faster sepsis detection broadens the addressable market in U.S. hospital laboratories. Peers have also had a strong week: BRKR surged 22% and Agilent rose 17%, suggesting the sector tailwind is real rather than company-specific. But WAT outperformed both on the month, which partly explains why shorts are adding: relative outperformance at elevated multiples is exactly the kind of setup that invites incremental bearish positioning.
What to watch: the gap between the bullish options flow and the rising short base is the key metric heading into Q2 results on August 4. Whether borrow costs begin to climb — currently anchored near the lowest levels of the past six months — will signal whether the short thesis is attracting serious committed capital or remains opportunistic and shallow.
See the live data behind this article on ORTEX.
Open WAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
